|Bid||109.39 x 800|
|Ask||109.38 x 800|
|Day's Range||108.20 - 109.56|
|52 Week Range||79.11 - 121.53|
|Beta (5Y Monthly)||0.83|
|PE Ratio (TTM)||29.50|
|Earnings Date||Oct. 29, 2021|
|Forward Dividend & Yield||5.20 (4.79%)|
|Ex-Dividend Date||Oct. 14, 2021|
|1y Target Est||127.01|
AbbVie's (ABBV) third-quarter results are expected to reflect the impact of a strong recovery in demand for new drugs. Investors are likely to focus on any update related to guidance.
Investors in search of stable income should consider strong dividend-paying stocks, with solid yields. Pharmaceutical standout AbbVie appears to be worth buying as a long-term play, with it set to release its Q3 results on Friday, October 29...
AbbVie (ABBV) closed at $108.50 in the latest trading session, marking a -0.59% move from the prior day.